Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Intercept Turns To RWE To Confirm Ocaliva’s Benefit In PBC After NASH Complete Response Letter
Jun 23 2023
•
By
Sue Sutter
Intercept's plan for pivoting to near-term profitability includes discontinuing OCA's development in NASH. • Source: Shutterstock
More from Product Reviews
More from Pink Sheet